4dgy › Citations

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M
Proc Natl Acad Sci U S A 109 9499-504 (2012)
Cited: 107 times
EuropePMC logo PMID: 22623528

Abstract

Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is genetically diverse, and therefore a broadly effective vaccine must target conserved T- and B-cell epitopes of the virus. Human mAb HCV1 has broad neutralizing activity against HCV isolates from at least four major genotypes and protects in the chimpanzee model from primary HCV challenge. The antibody targets a conserved antigenic site (residues 412-423) on the virus E2 envelope glycoprotein. Two crystal structures of HCV1 Fab in complex with an epitope peptide at 1.8-Å resolution reveal that the epitope is a β-hairpin displaying a hydrophilic face and a hydrophobic face on opposing sides of the hairpin. The antibody predominantly interacts with E2 residues Leu(413) and Trp(420) on the hydrophobic face of the epitope, thus providing an explanation for how HCV isolates bearing mutations at Asn(415) on the same binding face escape neutralization by this antibody. The results provide structural information for a neutralizing epitope on the HCV E2 glycoprotein and should help guide rational design of HCV immunogens to elicit similar broadly neutralizing antibodies through vaccination.

Reviews - 4dgy mentioned but not cited (11)

  1. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Bailey JR, Barnes E, Cox AL. Gastroenterology 156 418-430 (2019)
  2. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Lavie M, Hanoulle X, Dubuisson J. Front Immunol 9 910 (2018)
  3. Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. Fuerst TR, Pierce BG, Keck ZY, Foung SKH. Front Microbiol 8 2692 (2017)
  4. Viral evasion and challenges of hepatitis C virus vaccine development. Pierce BG, Keck ZY, Foung SK. Curr Opin Virol 20 55-63 (2016)
  5. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  6. Hepatitis C virus vaccine design: focus on the humoral immune response. Sepulveda-Crespo D, Resino S, Martinez I. J Biomed Sci 27 78 (2020)
  7. Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition. Guest JD, Pierce BG. Front Immunol 9 1117 (2018)
  8. Peptides for Vaccine Development. Hamley IW. ACS Appl Bio Mater 5 905-944 (2022)
  9. Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder. Yost SA, Wang Y, Marcotrigiano J. Front Immunol 9 1917 (2018)
  10. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Pathogens 10 685 (2021)
  11. Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies. Gomez-Escobar E, Roingeard P, Beaumont E. Viruses 15 1151 (2023)

Articles - 4dgy mentioned but not cited (8)

  1. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. Proc Natl Acad Sci U S A 109 9499-9504 (2012)
  2. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA. J Biol Chem 290 10117-10125 (2015)
  3. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Pierce BG, Boucher EN, Piepenbrink KH, Ejemel M, Rapp CA, Thomas WD, Sundberg EJ, Weng Z, Wang Y. J Virol 91 e01032-17 (2017)
  4. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE. J Virol 92 e02066-17 (2018)
  5. Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein. Stejskal L, Lees WD, Moss DS, Palor M, Bingham RJ, Shepherd AJ, Grove J. PLoS Comput Biol 16 e1007710 (2020)
  6. Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins. Devaurs D, Antunes DA, Hall-Swan S, Mitchell N, Moll M, Lizée G, Kavraki LE. BMC Mol Cell Biol 20 42 (2019)
  7. In Silico Analysis of Neutralizing Antibody Epitopes on The Hepatitis C Virus Surface Glycoproteins. Zareh-Khoshchehreh R, Bamdad T, Arab SS, Behdani M, Biglar M. Cell J 25 62-72 (2023)
  8. Structural Features of Antibody-Peptide Recognition. Lee JH, Yin R, Ofek G, Pierce BG. Front Immunol 13 910367 (2022)


Reviews citing this publication (28)

  1. Current progress in development of hepatitis C virus vaccines. Liang TJ. Nat Med 19 869-878 (2013)
  2. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Davidson E, Doranz BJ. Immunology 143 13-20 (2014)
  3. The past, present and future of neutralizing antibodies for hepatitis C virus. Ball JK, Tarr AW, McKeating JA. Antiviral Res 105 100-111 (2014)
  4. The secret life of viral entry glycoproteins: moonlighting in immune evasion. Cook JD, Lee JE. PLoS Pathog 9 e1003258 (2013)
  5. CD81 and hepatitis C virus (HCV) infection. Fénéant L, Levy S, Cocquerel L. Viruses 6 535-572 (2014)
  6. Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Drummer HE. Front Microbiol 5 329 (2014)
  7. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Expert Rev Vaccines 15 1535-1544 (2016)
  8. The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Tzarum N, Wilson IA, Law M. Front Immunol 9 1315 (2018)
  9. Computational tools for epitope vaccine design and evaluation. He L, Zhu J. Curr Opin Virol 11 103-112 (2015)
  10. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Kong L, Jackson KN, Wilson IA, Law M. Curr Opin Virol 11 148-157 (2015)
  11. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Sautto G, Tarr AW, Mancini N, Clementi M. Clin Dev Immunol 2013 450963 (2013)
  12. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Kinchen VJ, Cox AL, Bailey JR. Trends Microbiol 26 854-864 (2018)
  13. Expression of recombinant glycoproteins in mammalian cells: towards an integrative approach to structural biology. Aricescu AR, Owens RJ. Curr Opin Struct Biol 23 345-356 (2013)
  14. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Viruses 7 3995-4046 (2015)
  15. HCV glycoprotein structures: what to expect from the unexpected. Khan AG, Miller MT, Marcotrigiano J. Curr Opin Virol 12 53-58 (2015)
  16. Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2. Ströh LJ, Nagarathinam K, Krey T. Front Immunol 9 1396 (2018)
  17. Structural Vaccinology for Viral Vaccine Design. Anasir MI, Poh CL. Front Microbiol 10 738 (2019)
  18. HCV E2 core structures and mAbs: something is still missing. Castelli M, Clementi N, Sautto GA, Pfaff J, Kahle KM, Barnes T, Doranz BJ, Dal Peraro M, Clementi M, Burioni R, Mancini N. Drug Discov Today 19 1964-1970 (2014)
  19. Why is it so difficult to develop a hepatitis C virus preventive vaccine? Zingaretti C, De Francesco R, Abrignani S. Clin Microbiol Infect 20 Suppl 5 103-109 (2014)
  20. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Shahid I, ALMalki WH, Hafeez MH, Hassan S. Crit Rev Microbiol 42 535-547 (2016)
  21. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development. Ströh LJ, Krey T. Int J Mol Sci 21 E6781 (2020)
  22. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Vaccines (Basel) 9 291 (2021)
  23. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Guest JD, Pierce BG. Viruses 13 837 (2021)
  24. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Schlotthauer F, McGregor J, Drummer HE. Viruses 13 805 (2021)
  25. From Structural Studies to HCV Vaccine Design. Yechezkel I, Law M, Tzarum N. Viruses 13 833 (2021)
  26. Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Toth EA, Chagas A, Pierce BG, Fuerst TR. Viruses 13 1027 (2021)
  27. Mechanisms of HCV resistance to broadly neutralizing antibodies. Frumento N, Flyak AI, Bailey JR. Curr Opin Virol 50 23-29 (2021)
  28. Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine. Toth EA, Andrianov AK, Fuerst TR. Rev Med Virol 33 e2474 (2023)

Articles citing this publication (60)

  1. Rational HIV immunogen design to target specific germline B cell receptors. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. Science 340 711-716 (2013)
  2. Hepatitis C virus E2 envelope glycoprotein core structure. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. Science 342 1090-1094 (2013)
  3. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J. Nature 509 381-384 (2014)
  4. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Hepatology 59 2140-2151 (2014)
  5. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, Takeda K, Date S, Cheung TK, Phung Q, Hass P, Arnott D, Hongo JA, Matthews DJ, Brown A, Patel AH, Kelley RF, Eigenbrot C, Kapadia SB. J Mol Biol 425 1899-1914 (2013)
  6. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, Ray SC, Crowe JE. JCI Insight 2 92872 (2017)
  7. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ. Cell Host Microbe 24 703-716.e3 (2018)
  8. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH. J Virol 86 12923-12932 (2012)
  9. Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. Krey T, Meola A, Keck ZY, Damier-Piolle L, Foung SK, Rey FA. PLoS Pathog 9 e1003364 (2013)
  10. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL, Wilson IA, Law M. J Virol 86 13085-13088 (2012)
  11. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC. J Clin Invest 125 437-447 (2015)
  12. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T. J Virol 89 2170-2181 (2015)
  13. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, Foung SK. J Virol 90 3112-3122 (2016)
  14. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH. Proc Natl Acad Sci U S A 113 E6946-E6954 (2016)
  15. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL, Ward AB, Li S, Wilson IA, Law M. Proc Natl Acad Sci U S A 113 12768-12773 (2016)
  16. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T. Hepatology 58 932-939 (2013)
  17. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, Pfaff JM, Barnes T, Honda A, Giang E, Davidson E, Wilson IA, Doranz BJ, Law M. PLoS Pathog 13 e1006735 (2017)
  18. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. He L, Cheng Y, Kong L, Azadnia P, Giang E, Kim J, Wood MR, Wilson IA, Law M, Zhu J. Sci Rep 5 12501 (2015)
  19. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK. PLoS Pathog 10 e1004297 (2014)
  20. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE. Hepatology 65 1117-1131 (2017)
  21. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region. Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Vietheer PT, Edwards S, Quinn C, Coulibaly F, Poumbourios P, Drummer HE. J Virol 89 12245-12261 (2015)
  22. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. Ruwona TB, Giang E, Nieusma T, Law M. J Virol 88 10459-10471 (2014)
  23. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR. Proc Natl Acad Sci U S A 115 E82-E91 (2018)
  24. Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Deng L, Zhong L, Struble E, Duan H, Ma L, Harman C, Yan H, Virata ML, Zhao Z, Feinstone S, Alter H, Zhang P. Proc Natl Acad Sci U S A 110 7418-7422 (2013)
  25. Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. Kong L, Kadam RU, Giang E, Ruwona TB, Nieusma T, Culhane JC, Stanfield RL, Dawson PE, Wilson IA, Law M. J Mol Biol 427 2617-2628 (2015)
  26. Potential neutralizing antibodies discovered for novel corona virus using machine learning. Magar R, Yadav P, Barati Farimani A. Sci Rep 11 5261 (2021)
  27. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Sci Adv 6 eaaz6225 (2020)
  28. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE, Bailey JR. J Virol 93 e02070-18 (2019)
  29. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T, Marcotrigiano J, Rey FA, Patel AH, Krey T. mBio 8 e00382-17 (2017)
  30. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M. J Virol 90 3745-3759 (2016)
  31. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Wasilewski LN, El-Diwany R, Munshaw S, Snider AE, Brady JK, Osburn WO, Ray SC, Bailey JR. J Virol 90 3773-3782 (2016)
  32. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P. Hepatology 63 1120-1134 (2016)
  33. Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. Cao L, Yu B, Kong D, Cong Q, Yu T, Chen Z, Hu Z, Chang H, Zhong J, Baker D, He Y. PLoS Pathog 15 e1007759 (2019)
  34. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. Mathiesen CK, Prentoe J, Meredith LW, Jensen TB, Krarup H, McKeating JA, Gottwein JM, Bukh J. J Virol 89 7758-7775 (2015)
  35. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, STOP-HCV Consortium, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V. Elife 8 e42463 (2019)
  36. Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. Kachko A, Frey SE, Sirota L, Ray R, Wells F, Zubkova I, Zhang P, Major ME. Hepatology 62 1670-1682 (2015)
  37. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce BG, Molrine DC, Weng Z. PLoS One 9 e100325 (2014)
  38. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. Wijesundara DK, Wijesundara DK, Gummow J, Li Y, Yu W, Quah BJ, Ranasinghe C, Torresi J, Gowans EJ, Grubor-Bauk B. J Virol 92 e02133-17 (2018)
  39. Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus. Bazzill JD, Ochyl LJ, Giang E, Castillo S, Law M, Moon JJ. Nano Lett 18 7832-7838 (2018)
  40. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. Center RJ, Boo I, Phu L, McGregor J, Poumbourios P, Drummer HE. J Biol Chem 295 7179-7192 (2020)
  41. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, Kerzic MC, Marin A, Andrianov AK, Ball JK, Mariuzza RA, Fuerst TR, Foung SKH. J Virol 94 e00704-20 (2020)
  42. Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W. J Virol 91 e00479-17 (2017)
  43. Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A. J Immunol 197 4848-4858 (2016)
  44. Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors. Aleman F, Tzarum N, Kong L, Nagy K, Zhu J, Wilson IA, Law M. Proc Natl Acad Sci U S A 115 7569-7574 (2018)
  45. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. Cowton VM, Angus AGN, Cole SJ, Markopoulou CK, Owsianka A, Dunlop JI, Gardner DE, Krey T, Patel AH. J Virol 90 7456-7468 (2016)
  46. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, Taylor GL, Patel AH. NPJ Vaccines 6 7 (2021)
  47. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. Pedersen J, Jensen TB, Carlsen TH, Schønning K, Christensen PB, Laursen AL, Krarup H, Bukh J, Weis N. PLoS One 8 e62674 (2013)
  48. Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Cowton VM, Singer JB, Gifford RJ, Patel AH. Front Immunol 9 1470 (2018)
  49. Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. Alhammad YM, Maharajh S, Butcher R, Eden JS, White PA, Poumbourios P, Drummer HE. PLoS One 10 e0126397 (2015)
  50. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Pfaff-Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE, Law M, Doranz BJ. Cell Rep 39 110859 (2022)
  51. Prediction of linear B-cell epitopes of hepatitis C virus for vaccine development. Huang WL, Tsai MJ, Hsu KT, Wang JR, Chen YH, Ho SY. BMC Med Genomics 8 Suppl 4 S3 (2015)
  52. Unraveling hepatitis C virus structure. Fauvelle C, Felmlee DJ, Baumert TF. Cell Res 24 385-386 (2014)
  53. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. McGregor J, Hardy JM, Lay CS, Boo I, Piontek M, Suckow M, Coulibaly F, Poumbourios P, Center RJ, Drummer HE. J Virol 96 e0167521 (2022)
  54. Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. Ruwona TB, Mcbride R, Chappel R, Head SR, Ordoukhanian P, Burton DR, Law M. J Immunol Methods 402 35-42 (2014)
  55. The unexpected structures of hepatitis C virus envelope proteins. Wang Y, Wang J, Wu S, Zhu H. Exp Ther Med 14 1859-1865 (2017)
  56. Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, Aizaki H, Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R. Sci Rep 6 28688 (2016)
  57. Convergent antibody responses are associated with broad neutralization of hepatitis C virus. Skinner NE, Ogega CO, Frumento N, Clark KE, Yegnasubramanian S, Schuebel K, Meyers J, Gupta A, Wheelan S, Cox AL, Crowe JE, Ray SC, Bailey JR. Front Immunol 14 1135841 (2023)
  58. Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412-425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles. Czarnota A, Offersgaard A, Owsianka A, Alzua GP, Bukh J, Gottwein JM, Patel AH, Bieńkowska-Szewczyk K, Grzyb K. Microbiol Spectr e0254622 (2023)
  59. Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a. Zhang H, Quadeer AA, McKay MR. iScience 25 103569 (2022)
  60. HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies. Zhang H, Bull RA, Quadeer AA, McKay MR. Virus Evol 9 vead068 (2023)


Quick links